T1	tradename 0 8	ADCETRIS
T3	nanoparticle 11 31	brentuximab vedotin)
T5	tradename 139 147	ADCETRIS
T7	tradename 211 229	ADCETRIS. ADCETRIS
T9	nanoparticle 232 252	brentuximab vedotin)
T11	routeofadministration 272 283	intravenous
T13	fdaapprovaldate 311 315	2011
T15	adversereaction 325 373	PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)
T17	tradename 515 523	ADCETRIS
T19	tradename 811 819	ADCETRIS
T21	chemoclass 825 838	CD30-directed
T23	nanoparticle 839 862	antibody-drug conjugate
T25	indication 905 921	Hodgkin lymphoma
T27	tradename 1099 1099	
T29	indication 1099 1138	Systemic anaplastic large cell lymphoma
T31	routeofadministration 1649 1660	intravenous
T33	frequency 1686 1700	every 3 weeks.
T35	dose 1726 1735	1.8 mg/kg
T37	tradename 2213 2213	
T39	adversereaction 2213 2235	Peripheral neuropathy:
T41	tradename 2321 2321	
T43	adversereaction 2321 2356	Anaphylaxis and infusion reactions:
T45	adversereaction 2363 2380	infusion reaction
T47	adversereaction 2418 2429	anaphylaxis
T49	tradename 2483 2483	
T51	adversereaction 2483 2506	Hematologic toxicities:
T53	tradename 2559 2571	ADCETRIS. 
T55	adversereaction 2611 2635	Grade 3 or 4 neutropenia
T57	tradename 2748 2748	
T59	adversereaction 2748 2796	Serious infections and opportunistic infections:
T61	adversereaction 2843 2852	bacterial
T63	adversereaction 2854 2880	fungal or viral infections
T65	tradename 2889 2889	
T67	adversereaction 2889 2910	Tumor lysis syndrome:
T69	tradename 2998 2998	
T71	adversereaction 2998 3013	Hepatotoxicity:
T73	tradename 3058 3058	
T75	adversereaction 3058 3089	Serious dermatologic reactions:
T77	tradename 3176 3176	
T79	adversereaction 3176 3198	Embryo-fetal toxicity:
T81	adversereaction 3432 3443	neutropenia
T83	adversereaction 3445 3474	peripheral sensory neuropathy
T85	adversereaction 3476 3483	fatigue
T87	adversereaction 3485 3491	nausea
T89	adversereaction 3493 3499	anemia
T91	adversereaction 3501 3534	upper respiratory tract infection
T93	adversereaction 3536 3544	diarrhea
T95	adversereaction 3546 3553	pyrexia
T97	adversereaction 3555 3559	rash
T99	adversereaction 3561 3577	thrombocytopenia
T101	adversereaction 3579 3584	cough
T103	adversereaction 3590 3598	vomiting
T105	company 3654 3670	Seattle Genetics
T107	company 3672 3676	Inc.
T109	activeingredient 3958 3988	monomethyl auristatin E (MMAE)
T111	activeingredient 4142 4146	MMAE
T113	adversereaction 4387 4435	PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)
T115	indication 4468 4484	Hodgkin Lymphoma
T117	indication 4490 4529	Systemic Anaplastic Large Cell Lymphoma
T119	adversereaction 4753 4774	Peripheral Neuropathy
T121	adversereaction 4781 4815	Anaphylaxis and Infusion Reactions
T123	adversereaction 4822 4844	Hematologic Toxicities
T125	adversereaction 4851 4898	Serious Infections and Opportunistic Infections
T127	adversereaction 4905 4925	Tumor Lysis Syndrome
T129	adversereaction 4932 4993	Increased Toxicity in the Presence of Severe Renal Impairment
T131	adversereaction 5000 5075	Increased Toxicity in the Presence of Moderate or Severe Hepatic Impairment
T133	adversereaction 5082 5096	Hepatotoxicity
T135	adversereaction 5103 5145	Progressive Multifocal Leukoencephalopathy
T137	adversereaction 5153 5183	Serious Dermatologic Reactions
T139	adversereaction 5191 5212	Embryo-Fetal Toxicity
T141	tradename 5350 5359	ADCETRIS 
T143	tradename 5374 5382	ADCETRIS
T145	indication 5800 5816	Hodgkin Lymphoma
T147	indication 5823 5862	Systemic Anaplastic Large Cell Lymphoma
T149	tradename 6272 6280	ADCETRIS
T151	indication 6378 6394	Hodgkin Lymphoma
T153	tradename 6396 6404	ADCETRIS
T155	nanoparticle 6406 6426	brentuximab vedotin)
T157	indication 6471 6492	Hodgkin lymphoma (HL)
T159	indication 7006 7045	Systemic Anaplastic Large Cell Lymphoma
T161	tradename 7047 7055	ADCETRIS
T163	indication 7100 7147	systemic anaplastic large cell lymphoma (sALCL)
T165	tradename 7627 7635	ADCETRIS
T167	routeofadministration 7642 7653	intravenous
T169	frequency 7679 7692	every 3 weeks
T171	tradename 7817 7825	ADCETRIS
T173	dose 7896 7918	1.8 mg/kg up to 180 mg
T175	dose 8043 8065	1.8 mg/kg up to 180 mg
T177	dose 8203 8225	1.2 mg/kg up to 120 mg
T179	dose 8512 8522	1.2 mg/kg.
T181	tradename 8559 8567	ADCETRIS
T183	tradename 8620 8628	ADCETRIS
T185	tradename 8981 8989	ADCETRIS
T187	dose 8993 9003	1.2 mg/kg.
T189	tradename 9085 9093	ADCETRIS
T191	routeofadministration 9100 9111	intravenous
T193	tradename 9139 9147	ADCETRIS
T195	indication 9286 9296	anticancer
T197	tradename 9595 9603	ADCETRIS
T199	nanoparticle 9704 9724	brentuximab vedotin.
T201	tradename 10382 10390	ADCETRIS
T203	nanoparticle 10671 10691	brentuximab vedotin.
T205	tradename 10770 10778	ADCETRIS
T207	dose 10987 10992	50 mg
T209	nanoparticle 10996 11015	brentuximab vedotin
T211	tradename 11159 11168	 ADCETRIS
T213	adversereaction 11361 11382	Peripheral Neuropathy
T215	tradename 11384 11392	ADCETRIS
T217	adversereaction 11412 11433	peripheral neuropathy
T219	adversereaction 11476 11503	peripheral motor neuropathy
T221	tradename 11531 11547	ADCETRIS-induced
T223	adversereaction 11548 11569	peripheral neuropathy
T225	indication 11592 11594	HL
T227	indication 11599 11604	sALCL
T229	adversereaction 11663 11674	neuropathy.
T231	adversereaction 11812 11822	neuropathy
T233	adversereaction 11841 11851	neuropathy
T235	adversereaction 11925 11935	neuropathy
T237	adversereaction 11945 11957	hypoesthesia
T239	adversereaction 11959 11972	hyperesthesia
T241	adversereaction 11974 11985	paresthesia
T243	adversereaction 11987 11997	discomfort
T245	adversereaction 11999 12018	a burning sensation
T247	adversereaction 12020 12036	neuropathic pain
T249	adversereaction 12041 12050	weakness.
T251	adversereaction 12092 12113	peripheral neuropathy
T253	tradename 12173 12181	ADCETRIS
T255	adversereaction 12218 12279	Anaphylaxis and Infusion Reactions Infusion-related reactions
T257	adversereaction 12291 12302	anaphylaxis
T259	tradename 12323 12335	ADCETRIS. 
T261	adversereaction 12374 12385	anaphylaxis
T263	tradename 12452 12460	ADCETRIS
T265	adversereaction 12513 12538	infusion-related reaction
T267	co-administereddrug 12771 12784	acetaminophen
T269	co-administereddrug 12789 12802	antihistamine
T271	co-administereddrug 12810 12825	corticosteroid.
T273	adversereaction 12832 12854	Hematologic Toxicities
T275	adversereaction 12890 12901	neutropenia
T277	adversereaction 12906 12941	Grade 3 or Grade 4 thrombocytopenia
T279	adversereaction 12945 12951	anemia
T281	tradename 12967 12979	ADCETRIS. 
T283	adversereaction 12979 12998	Febrile neutropenia
T285	tradename 13037 13049	ADCETRIS. 
T287	tradename 13113 13121	ADCETRIS
T289	adversereaction 13190 13215	Grade 3 or 4 neutropenia.
T291	adversereaction 13249 13273	Grade 3 or 4 neutropenia
T293	tradename 13372 13380	ADCETRIS
T295	adversereaction 13424 13471	Serious Infections and Opportunistic Infections
T297	tradename 13473 13473	
T299	adversereaction 13473 13520	Serious infections and opportunistic infections
T301	adversereaction 13529 13538	pneumonia
T303	adversereaction 13540 13550	bacteremia
T305	adversereaction 13556 13578	sepsis or septic shock
T307	tradename 13650 13662	ADCETRIS. 
T309	adversereaction 13746 13755	bacterial
T311	adversereaction 13757 13763	fungal
T313	adversereaction 13765 13785	or viral infections.
T315	adversereaction 13792 13812	Tumor Lysis Syndrome
T317	adversereaction 13906 13927	tumor lysis syndrome.
T319	adversereaction 13982 14043	Increased Toxicity in the Presence of Severe Renal Impairment
T321	adversereaction 14101 14107	deaths
T323	activeingredient 14226 14230	MMAE
T325	tradename 14405 14413	ADCETRIS
T327	adversereaction 14546 14621	Increased Toxicity in the Presence of Moderate or Severe Hepatic Impairment
T329	adversereaction 14679 14685	deaths
T331	tradename 14823 14831	ADCETRIS
T333	adversereaction 14964 14978	Hepatotoxicity
T335	adversereaction 14997 15011	hepatotoxicity
T337	adversereaction 15023 15037	fatal outcomes
T339	tradename 15075 15087	ADCETRIS. 
T341	tradename 15238 15246	ADCETRIS
T343	tradename 15256 15264	ADCETRIS
T345	adversereaction 15486 15500	hepatotoxicity
T347	tradename 15560 15572	ADCETRIS.  
T349	adversereaction 15576 15618	Progressive Multifocal Leukoencephalopathy
T351	adversereaction 15652 15655	PML
T353	adversereaction 15660 15665	death
T355	tradename 15687 15703	ADCETRIS-treated
T357	tradename 15730 15738	ADCETRIS
T359	adversereaction 15893 15896	PML
T361	tradename 16004 16012	ADCETRIS
T363	adversereaction 16046 16049	PML
T365	tradename 16066 16074	ADCETRIS
T367	adversereaction 16100 16103	PML
T369	adversereaction 16125 16155	Serious Dermatologic Reactions
T371	tradename 16157 16157	
T373	adversereaction 16157 16187	Stevens-Johnson syndrome (SJS)
T375	adversereaction 16192 16224	toxic epidermal necrolysis (TEN)
T377	adversereaction 16236 16250	fatal outcomes
T379	tradename 16276 16285	ADCETRIS.
T381	adversereaction 16290 16293	SJS
T383	adversereaction 16297 16300	TEN
T385	tradename 16321 16329	ADCETRIS
T387	adversereaction 16381 16402	Embryo-Fetal Toxicity
T389	tradename 16457 16465	ADCETRIS
T391	tradename 16554 16562	ADCETRIS
T393	tradename 16625 16625	
T395	nanoparticle 16625 16644	Brentuximab vedotin
T397	adversereaction 16652 16675	embryo-fetal toxicities
T399	adversereaction 16701 16727	decreased embryo viability
T401	adversereaction 16732 16751	fetal malformations
T403	adversereaction 17247 17268	Peripheral neuropathy
T405	tradename 17307 17307	
T407	adversereaction 17307 17341	Anaphylaxis and Infusion Reactions
T409	tradename 17380 17380	
T411	adversereaction 17380 17402	Hematologic Toxicities
T413	adversereaction 17448 17495	Serious Infections and Opportunistic Infections
T415	tradename 17534 17534	
T417	adversereaction 17534 17554	Tumor Lysis Syndrome
T419	tradename 17593 17593	
T421	adversereaction 17593 17654	Increased Toxicity in the Presence of Severe Renal Impairment
T423	tradename 17693 17693	
T425	adversereaction 17693 17768	Increased Toxicity in the Presence of Moderate or Severe Hepatic Impairment
T427	tradename 17807 17807	
T429	adversereaction 17807 17821	Hepatotoxicity
T431	tradename 17860 17860	
T433	adversereaction 17860 17902	Progressive Multifocal Leukoencephalopathy
T435	tradename 17941 17941	
T437	adversereaction 17941 17971	Serious Dermatologic Reactions
T439	tradename 18011 18011	
T441	adversereaction 18011 18032	Embryo-Fetal Toxicity
T443	tradename 18366 18374	ADCETRIS
T445	adversereaction 18541 18552	neutropenia
T447	adversereaction 18554 18583	peripheral sensory neuropathy
T449	adversereaction 18585 18592	fatigue
T451	adversereaction 18594 18600	nausea
T453	adversereaction 18602 18608	anemia
T455	adversereaction 18610 18643	upper respiratory tract infection
T457	adversereaction 18645 18653	diarrhea
T459	adversereaction 18655 18662	pyrexia
T461	adversereaction 18664 18668	rash
T463	adversereaction 18670 18686	thrombocytopenia
T465	adversereaction 18688 18693	cough
T467	adversereaction 18699 18708	vomiting.
T469	indication 18915 18931	Hodgkin Lymphoma
T471	tradename 18933 18941	ADCETRIS
T473	indication 18975 18977	HL
T475	dose 19065 19074	1.8 mg/kg
T477	routeofadministration 19075 19088	intravenously
T479	frequency 19089 19103	every 3 weeks.
T481	duration 19139 19147	27 weeks
T483	duration 19156 19170	3 to 56 weeks)
T485	adversereaction 19282 19293	neutropenia
T487	adversereaction 19295 19324	peripheral sensory neuropathy
T489	adversereaction 19326 19333	fatigue
T491	adversereaction 19335 19368	upper respiratory tract infection
T493	adversereaction 19370 19376	nausea
T495	adversereaction 19378 19386	diarrhea
T497	adversereaction 19388 19394	anemia
T499	adversereaction 19396 19403	pyrexia
T501	adversereaction 19405 19421	thrombocytopenia
T503	adversereaction 19423 19427	rash
T505	adversereaction 19429 19443	abdominal pain
T507	adversereaction 19445 19450	cough
T509	adversereaction 19456 19465	vomiting.
T511	tradename 19467 19468	 
T513	adversereaction 19468 19486	Pulmonary Toxicity
T515	indication 19531 19533	HL
T517	tradename 19547 19555	ADCETRIS
T519	adversereaction 19632 19650	pulmonary toxicity
T521	adversereaction 19792 19797	cough
T523	adversereaction 19802 19810	dyspnea.
T525	tradename 20004 20012	ADCETRIS
T527	indication 20092 20131	Systemic Anaplastic Large Cell Lymphoma
T529	tradename 20133 20141	ADCETRIS
T531	indication 20174 20179	sALCL
T533	dose 20267 20276	1.8 mg/kg
T535	routeofadministration 20277 20290	intravenously
T537	frequency 20291 20305	every 3 weeks.
T539	duration 20341 20349	24 weeks
T541	duration 20358 20372	3 to 56 weeks)
T543	adversereaction 20484 20495	neutropenia
T545	adversereaction 20497 20503	anemia
T547	adversereaction 20505 20534	peripheral sensory neuropathy
T549	adversereaction 20536 20543	fatigue
T551	adversereaction 20545 20551	nausea
T553	adversereaction 20553 20560	pyrexia
T555	adversereaction 20568 20576	diarrhea
T557	adversereaction 20582 20587	pain.
T559	tradename 20856 20856	
T561	adversereaction 20856 20868	Neutropenia*
T563	tradename 20870 20870	
T565	adversereaction 20870 20877	Anemia*
T567	tradename 20879 20879	
T569	adversereaction 20879 20896	Thrombocytopenia*
T571	tradename 20898 20898	
T573	adversereaction 20900 20915	Lymphadenopathy
T575	tradename 20945 20945	
T577	adversereaction 20945 20963	Peripheral sensory
T579	tradename 20971 20971	
T581	adversereaction 20971 20981	neuropathy
T583	tradename 20985 20985	
T585	adversereaction 20985 21001	Peripheral motor
T587	tradename 21008 21008	
T589	adversereaction 21008 21037	neuropathy Headache Dizziness
T591	tradename 21094 21094	
T593	adversereaction 21094 21101	Fatigue
T595	tradename 21103 21103	
T597	adversereaction 21103 21110	Pyrexia
T599	tradename 21112 21112	
T601	adversereaction 21112 21118	Chills
T603	tradename 21120 21120	
T605	adversereaction 21120 21124	Pain
T607	tradename 21126 21127	 
T609	adversereaction 21127 21143	Edema peripheral
T611	tradename 21173 21173	
T613	adversereaction 21173 21206	Upper respiratory tract infection
T615	tradename 21236 21236	
T617	adversereaction 21236 21242	Nausea
T619	tradename 21244 21244	
T621	adversereaction 21244 21252	Diarrhea
T623	tradename 21254 21254	
T625	adversereaction 21254 21268	Abdominal pain
T627	tradename 21270 21270	
T629	adversereaction 21270 21278	Vomiting
T631	tradename 21280 21280	
T633	adversereaction 21280 21292	Constipation
T635	tradename 21334 21334	
T637	adversereaction 21334 21338	Rash
T639	tradename 21340 21340	
T641	adversereaction 21340 21348	Pruritus
T643	tradename 21350 21350	
T645	adversereaction 21350 21358	Alopecia
T647	tradename 21360 21360	
T649	adversereaction 21360 21372	Night sweats
T651	tradename 21374 21374	
T653	adversereaction 21374 21382	Dry skin
T655	tradename 21693 21694	 
T657	indication 21694 21696	HL
T659	tradename 21726 21726	
T661	indication 21726 21731	sALCL
T663	tradename 21905 21905	
T665	adversereaction 21905 21912	Dyspnea
T667	tradename 21927 21928	 
T669	adversereaction 21928 21946	Oropharyngeal pain
T671	tradename 22011 22011	
T673	adversereaction 22011 22021	Arthralgia
T675	tradename 22035 22035	
T677	adversereaction 22035 22042	Myalgia
T679	tradename 22057 22057	
T681	adversereaction 22057 22066	Back pain
T683	tradename 22081 22081	
T685	adversereaction 22081 22098	Pain in extremity
T687	tradename 22114 22115	 
T689	adversereaction 22115 22128	Muscle spasms
T691	tradename 22166 22166	
T693	adversereaction 22166 22174	Insomnia
T695	tradename 22189 22189	
T697	adversereaction 22189 22196	Anxiety
T699	tradename 22247 22247	
T701	adversereaction 22247 22265	Decreased appetite
T703	tradename 22295 22295	
T705	adversereaction 22295 22311	Weight decreased
T707	tradename 22385 22385	
T709	adversereaction 22385 22403	Infusion reactions
T711	adversereaction 22418 22429	anaphylaxis
T713	adversereaction 22492 22518	infusion-related reactions
T715	adversereaction 22573 22599	infusion-related reactions
T717	adversereaction 22702 22728	infusion-related reactions
T719	adversereaction 22734 22740	chills
T721	adversereaction 22747 22753	nausea
T723	adversereaction 22760 22767	dyspnea
T725	adversereaction 22774 22782	pruritus
T727	adversereaction 22789 22796	pyrexia
T729	adversereaction 22807 22812	cough
T731	tradename 22966 22977	ADCETRIS. 
T733	indication 23048 23050	HL
T735	adversereaction 23059 23086	peripheral motor neuropathy
T737	adversereaction 23093 23107	abdominal pain
T739	adversereaction 23114 23132	pulmonary embolism
T741	adversereaction 23139 23150	pneumonitis
T743	adversereaction 23157 23169	pneumothorax
T745	adversereaction 23176 23190	pyelonephritis
T747	adversereaction 23201 23208	pyrexia
T749	indication 23288 23293	sALCL
T751	adversereaction 23299 23311	septic shock
T753	adversereaction 23318 23345	supraventricular arrhythmia
T755	adversereaction 23352 23369	pain in extremity
T757	adversereaction 23380 23403	urinary tract infection
T759	adversereaction 23470 23473	PML
T761	adversereaction 23475 23499	Stevens-Johnson syndrome
T763	adversereaction 23505 23526	tumor lysis syndrome.
T765	adversereaction 23624 23635	neutropenia
T767	adversereaction 23646 23675	peripheral sensory neuropathy
T769	indication 23895 23897	HL
T771	indication 23901 23906	sALCL
T773	adversereaction 23912 23941	peripheral sensory neuropathy
T775	adversereaction 23951 23978	peripheral motor neuropathy
T777	tradename 24099 24111	ADCETRIS. 
T779	adversereaction 24352 24371	febrile neutropenia
T781	adversereaction 24436 24450	hepatotoxicity
T783	adversereaction 24501 24504	PML
T785	adversereaction 24565 24605	 infections and opportunistic infections
T787	adversereaction 24681 24695	hyperglycemia.
T789	adversereaction 24725 24737	Pancreatitis
T791	adversereaction 24899 24925	Toxic epidermal necrolysis
T793	indication 25027 25029	HL
T795	indication 25034 25039	sALCL
T797	nanoparticle 25120 25139	brentuximab vedotin
T799	frequency 25140 25153	every 3 weeks
T801	nanoparticle 25519 25538	brentuximab vedotin
T803	adversereaction 25813 25839	infusion related reactions
T805	tradename 26585 26593	ADCETRIS
T807	activeingredient 26716 26746	monomethyl auristatin E (MMAE)
T809	activeingredient 26821 26825	MMAE
T811	tradename 26926 26936	ADCETRIS 
T813	activeingredient 26964 26968	MMAE
T815	tradename 27061 27069	ADCETRIS
T817	activeingredient 27138 27142	MMAE
T819	tradename 27238 27246	ADCETRIS
T821	tradename 27320 27328	ADCETRIS
T823	activeingredient 27389 27393	MMAE
T825	tradename 27455 27463	ADCETRIS
T827	activeingredient 27510 27515	MMAE.
T829	tradename 27579 27587	ADCETRIS
T831	tradename 27655 27663	ADCETRIS
T833	tradename 27701 27709	ADCETRIS
T835	tradename 27770 27770	
T837	activeingredient 27770 27774	MMAE
T839	tradename 27883 27891	ADCETRIS
T841	tradename 28159 28167	ADCETRIS
T843	tradename 28255 28263	ADCETRIS
T845	tradename 28326 28326	
T847	nanoparticle 28326 28345	Brentuximab vedotin
T849	adversereaction 28353 28376	embryo-fetal toxicities
T851	indication 28490 28492	HL
T853	indication 28497 28503	sALCL.
T855	routeofadministration 28757 28768	intravenous
T857	dose 28778 28781	0.3
T859	dose 28783 28784	1
T861	dose 28786 28787	3
T863	dose 28789 28800	or 10 mg/kg
T865	nanoparticle 28801 28820	brentuximab vedotin
T867	adversereaction 28910 28933	embryo-fetal toxicities
T869	dose 28975 28989	3 and 10 mg/kg
T871	nanoparticle 29247 29266	brentuximab vedotin
T873	dose 29275 29282	3 mg/kg
T875	indication 29335 29337	HL
T877	indication 29341 29346	sALCL
T879	dose 29384 29393	1.8 mg/kg
T881	frequency 29394 29412	every three weeks.
T883	nanoparticle 29460 29479	brentuximab vedotin
T885	tradename 29638 29646	ADCETRIS
T887	tradename 29847 29855	ADCETRIS
T889	tradename 29930 29938	ADCETRIS
T891	tradename 30115 30123	ADCETRIS
T893	tradename 30347 30355	ADCETRIS
T895	activeingredient 30495 30526	monomethyl auristatin E (MMAE).
T897	nanoparticle 30563 30582	brentuximab vedotin
T899	activeingredient 30587 30591	MMAE
T901	dose 30635 30644	1.2 mg/kg
T903	tradename 30648 30656	ADCETRIS
T905	activeingredient 30990 30994	MMAE
T907	tradename 31009 31018	ADCETRIS)
T909	activeingredient 31157 31161	MMAE
T911	tradename 31360 31368	ADCETRIS
T913	activeingredient 31501 31506	MMAE.
T915	nanoparticle 31543 31562	brentuximab vedotin
T917	activeingredient 31567 31571	MMAE
T919	tradename 31628 31636	ADCETRIS
T921	activeingredient 31967 31971	MMAE
T923	tradename 32158 32167	ADCETRIS.
T925	tradename 32348 32357	 ADCETRIS
T927	nanoparticle 32359 32379	brentuximab vedotin)
T929	chemoclass 32385 32398	CD30-directed
T931	nanoparticle 32399 32428	antibody-drug conjugate (ADC)
T933	chemoclass 32530 32558	microtubule disrupting agent
T935	activeingredient 32559 32563	MMAE
T937	activeingredient 32625 32629	MMAE
T939	tradename 32641 32641	
T941	nanoparticle 32641 32660	Brentuximab vedotin
T943	molecularweight 32700 32708	153 kDa.
T945	activeingredient 32739 32743	MMAE
T947	tradename 32785 32785	
T949	nanoparticle 32786 32805	Brentuximab vedotin
T951	tradename 33031 33039	ADCETRIS
T953	nanoparticle 33041 33061	brentuximab vedotin)
T955	inactiveingredient 33236 33241	Water
T957	nanoparticle 33292 33311	brentuximab vedotin
T959	inactiveingredient 33370 33389	trehalose dihydrate
T961	inactiveingredient 33401 33425	sodium citrate dihydrate
T963	inactiveingredient 33438 33461	citric acid monohydrate
T965	inactiveingredient 33478 33492	polysorbate 80
T967	inactiveingredient 33497 33502	water
T969	tradename 33602 33602	
T971	nanoparticle 33602 33621	Brentuximab vedotin
T973	nanoparticle 33628 33632	ADC.
T975	activeingredient 33711 33715	MMAE
T977	chemoclass 33722 33751	microtubule disrupting agent.
T979	tradename 33754 33754	
T981	activeingredient 33754 33758	MMAE
T983	indication 33847 33857	anticancer
T985	tradename 33870 33878	ADCETRIS
T987	nanoparticle 33908 33911	ADC
T989	nanoparticle 33973 33979	ADC-CD
T991	activeingredient 34010 34014	MMAE
T993	activeingredient 34054 34058	MMAE
T995	nanoparticle 34263 34282	brentuximab vedotin
T997	dose 34284 34294	1.8 mg/kg)
T999	nanoparticle 34455 34474	brentuximab vedotin
T1001	nanoparticle 34737 34756	brentuximab vedotin
T1003	nanoparticle 34923 34926	ADC
T1005	activeingredient 34928 34932	MMAE
T1007	nanoparticle 35032 35036	ADC.
T1009	nanoparticle 35066 35069	ADC
T1011	activeingredient 35074 35078	MMAE
T1013	nanoparticle 35139 35142	ADC
T1015	nanoparticle 35228 35231	ADC
T1017	plasmahalflife 35309 35321	4 to 6 days.
T1019	dose 35375 35392	1.2 to 2.7 mg/kg.
T1021	nanoparticle 35413 35416	ADC
T1023	tmax 35430 35444	within 21 days
T1025	frequency 35450 35462	every 3-week
T1027	tradename 35473 35481	ADCETRIS
T1029	nanoparticle 35563 35566	ADC
T1031	frequency 35607 35619	every 3-week
T1033	activeingredient 35669 35673	MMAE
T1035	tmax 35700 35712	1 to 3 days.
T1037	nanoparticle 35729 35732	ADC
T1039	activeingredient 35750 35754	MMAE
T1041	tmax 35768 35782	within 21 days
T1043	tmax 35788 35800	every 3 week
T1045	tradename 35811 35820	ADCETRIS.
T1047	activeingredient 35822 35826	MMAE
T1049	tradename 35880 35888	ADCETRIS
T1051	activeingredient 36028 36032	MMAE
T1053	activeingredient 36086 36090	MMAE
T1055	activeingredient 36178 36182	MMAE
T1057	volumeofdistribution 36322 36335	6&#x2013;10 L
T1059	nanoparticle 36340 36344	ADC.
T1061	activeingredient 36430 36434	MMAE
T1063	activeingredient 36449 36468	brentuximab vedotin
T1065	activeingredient 36519 36523	MMAE
T1067	activeingredient 36648 36652	MMAE
T1069	tradename 36701 36701	
T1071	activeingredient 36701 36705	MMAE
T1073	activeingredient 36801 36805	MMAE
T1075	activeingredient 36870 36874	MMAE
T1077	nanoparticle 36927 36931	ADC.
T1079	dose 37003 37012	1.8 mg/kg
T1081	tradename 37016 37025	ADCETRIS.
T1083	activeingredient 37057 37061	MMAE
T1085	nanoparticle 37090 37093	ADC
T1087	tradename 37104 37112	ADCETRIS
T1089	activeingredient 37200 37204	MMAE
T1091	activeingredient 37284 37288	MMAE
T1093	nanoparticle 37613 37633	brentuximab vedotin.
T1095	nanoparticle 37751 37770	brentuximab vedotin
T1097	activeingredient 37794 37799	MMAE)
T1099	tradename 37826 37826	
T1101	activeingredient 37826 37830	MMAE
T1103	activeingredient 37980 37984	MMAE
T1105	chemoclass 37990 38019	microtubule disrupting agent.
T1107	tradename 38022 38022	
T1109	activeingredient 38022 38026	MMAE
T1111	nanoparticle 38174 38193	brentuximab vedotin
T1113	activeingredient 38197 38201	MMAE
T1115	nanoparticle 38312 38331	brentuximab vedotin
T1117	duration 38390 38396	4-week
T1119	dose 38454 38457	0.5
T1121	dose 38459 38472	5 or 10 mg/kg
T1123	nanoparticle 38473 38492	brentuximab vedotin
T1125	dose 38648 38662	5 and 10 mg/kg
T1127	nanoparticle 38666 38686	brentuximab vedotin.
T1129	dose 38761 38770	1.8 mg/kg
T1131	indication 38837 38853	Hodgkin Lymphoma
T1133	tradename 38871 38879	ADCETRIS
T1135	indication 38897 38899	HL
T1137	dose 39060 39069	1.8 mg/kg
T1139	tradename 39073 39081	ADCETRIS
T1141	routeofadministration 39082 39095	intravenously
T1143	frequency 39112 39126	every 3 weeks.
T1145	indication 39933 39949	Hodgkin Lymphoma
T1147	indication 40240 40279	Systemic Anaplastic Large Cell Lymphoma
T1149	tradename 40297 40305	ADCETRIS
T1151	indication 40332 40337	sALCL
T1153	indication 40449 40454	sALCL
T1155	dose 40534 40543	1.8 mg/kg
T1157	tradename 40547 40555	ADCETRIS
T1159	routeofadministration 40569 40582	intravenously
T1161	frequency 40599 40613	every 3 weeks.
T1163	indication 41639 41678	Systemic Anaplastic Large Cell Lymphoma
T1165	tradename 42156 42164	ADCETRIS
T1167	nanoparticle 42166 42186	brentuximab vedotin)
T1169	nanoparticle 42358 42378	brentuximab vedotin.
T1171	tradename 42510 42518	ADCETRIS
T1173	tradename 42638 42638	
T1175	adversereaction 42638 42659	Peripheral neuropathy
T1177	tradename 42682 42690	ADCETRIS
T1179	adversereaction 42703 42725	peripheral neuropathy.
T1181	tradename 42898 42898	
T1183	adversereaction 42898 42915	Fever/Neutropenia
T1185	adversereaction 42976 42981	fever
T1187	tradename 43137 43137	
T1189	adversereaction 43137 43155	Infusion reactions
T1191	adversereaction 43258 43276	infusion reactions
T1193	tradename 43397 43397	
T1195	adversereaction 43397 43411	Hepatotoxicity
T1197	adversereaction 43466 43478	liver injury
T1199	tradename 43606 43606	
T1201	adversereaction 43606 43648	Progressive multifocal leukoencephalopathy
T1203	tradename 43678 43686	ADCETRIS
T1205	tradename 44116 44116	
T1207	adversereaction 44116 44128	Pancreatitis
T1209	tradename 44277 44286	 ADCETRIS
T1211	tradename 44334 44342	ADCETRIS
T1213	tradename 44502 44510	ADCETRIS
T1215	company 44575 44591	Seattle Genetics
T1217	company 44593 44597	Inc.
T1219	tradename 44650 44658	ADCETRIS
T1221	company 44660 44676	Seattle Genetics
T1223	company 44714 44730	Seattle Genetics
T1225	company 44732 44736	Inc.
